Navigation Links
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
Date:2/11/2009

December 31, December 31, 2008 2007 Cash flows from operating activities: Net loss $(51,064,241) $(74,069,690) Adjustments to reconcile net income to net cash used in operating activities: Depreciation and amortization 530,805 571,586 Stock-based compensation 13,387,789 19,622,814 Loss on disposal of assets (173) 28,713 Accretion of discount on investments (235,163) (1,571,905) Changes in assets and liabilities: Prepaid expenses and other current assets 495,200 168,987 Deposits 150,000 - Accounts payable (2,475,697) 204,029 Accrued expenses (6,892,577) 3,465,028 Deferred grant revenue - (147,464) Other liabilities 148,728 86,644 Net cash used in operating activities (45,955,329) (51,641,258) Cash flows from investing activities: Purchases of property and equipment (943,659) (279,433) Proceeds from sales of property and equipment - 200,179 Purchases of marketable securities (14,786,080) (138,953,879) Proceeds from sales of marketable securities 11,258,094 3,577,859 Maturities of marketable securities 47,560,000 86,695,000 Net cash provided by (used in) investing activities 43,088,355 (48,760,274) Cash flows from financing activities: Proceeds from exercise of stock options and warrants
'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
2. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
3. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
4. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
5. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
6. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
8. Sagent Pharmaceuticals Announces Expansion of Cefazolin Product Line to Include Cefazolin for Injection, USP in 500mg Single-Dose Vial
9. PacificGMP and LigoCyte Pharmaceuticals Announce cGMP Manufacturing Collaboration
10. Diffusion Pharmaceuticals Announces Completion of a $2.9 Million Private Placement and Company Presentations at Upcoming Industry Conferences in Geneva, Switzerland and Naples, Florida
11. Tigris Pharmaceuticals Files IND Application for GGTI-2418
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2015 BioLight Life Sciences ... "Company"), a firm that invests in, manages and ... announced today that presentations highlighting its IOPtiMate™ system ... at the Ophthalmology Futures European Forum and the ... & Refractive Surgeons ("ESCRS"), both taking place in ...
(Date:9/2/2015)... September 2, 2015 BiondVax Pharmaceuticals Ltd. ... National Institute of Allergy and Infectious Diseases (NIAID), part of ... of Health and Human Services (HHS), to launch a new ... United States in the 2015-16 timeframe. The trial ... Multimeric-001 (M-001), as a primer vaccine, which would be administered ...
(Date:9/2/2015)... 2, 2015 Biovista Inc. ... BeHEARD von 2015 bekanntgeben zu können. Hierbei handelt ... Institute. Biovista unterstützt mit seiner Möglichkeit ... Behandlung anderer Krankheiten als denen, für die ein ... und sein Team bei der Wylder Nation Foundation ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... critical demand to aid high-risk surgeries. From vital sign monitoring in ICU to ... Intel technology enables surgeon to make real-time clinical decisions with simultaneous access to ...
Breaking Biology Technology:Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 2Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 3
... few sentences? Does it possess a well-known identity ... ,In a 2005 study conducted by ABC Namebank International, ... results were compiled to measure the impact of their ... was also a strong emphasis on cyber-branding platforms and ...
... Image courtesy Promega Fitchburg, Wis. - ... division that sells and services small storage units that utilize ... , , Terso Solutions Inc ., was conceived in May ... the PromegaExpress technology, developed in 2002. Promega has ...
... less than three months until DEMO 2006, the screening and ... under way. A bit more than one-third of the class ... through hundreds more applications to bring the total number of ... at this point in the process, I begin to get ...
Cached Biology Technology:Does your company have an identity crisis? 2Does your company have an identity crisis? 3Promega spins off RFID 'smart appliance' company 2Promega spins off RFID 'smart appliance' company 3Promega spins off RFID 'smart appliance' company 4Promega spins off RFID 'smart appliance' company 5Promega spins off RFID 'smart appliance' company 6DEMO 2006: A sea change is coming 2DEMO 2006: A sea change is coming 3
(Date:8/28/2015)... According to a new market ... Type (Pen & Paper Based, Hosted, Biometrics), Service, Application ... Research), Vertical and Region - Global Forecast to 2020", ... grow from USD 2.4 Billion in 2015 to USD ... Rate (CAGR) of 25.6% from 2015 to 2020. ...
(Date:8/24/2015)...  Based on its recent analysis of the biometric products ... Biometrics Company of the Year Award. DERMALOG is the leading ... Africa . It has particularly gained prominence ... one of the largest biometric mass applications in the world, ... Bank of Nigeria with its biometric ...
(Date:8/19/2015)... , Aug. 19, 2015  VOXX International Corporation ... has entered into a Definitive Agreement to purchase ... iris authentication market leader EyeLock through an acquiring ... have a controlling interest in the acquiring entity. ... completion of due diligence.  Expanding on its existing ...
Breaking Biology News(10 mins):Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 2Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 3Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5
... natural ability of certain fungi to break down complex ... cell factories in industrial processes. Advances in metabolic engineering ... these fungi to produce specific bioproducts, as described in ... peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The ...
... , This news release is available in ... system, presented at Gregorio Maran Hospital, permits real-time interaction with the ... well as the radiotherapy applicator used to radiate the area affected ... surgery of cancers treated with intraoperative radiotherapy in the hope of ...
... worms that have become a major concern and source of ... article published today in the Canadian Journal of Animal ... control the disease. According to the paper, the ... parasites. Over time these drugs are less effective as helminths ...
Cached Biology News:Integrated approaches to customize fungal cell factories 2The first cancer operation room with a navigator is created 2The first cancer operation room with a navigator is created 3
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
The S. cerevisiae Hansen strains are the parental yeast strains from which the deletions were derived....
Tissue culture grade....
Mus musculus MARCKS-like protein, mRNA...
Biology Products: